Uterine Fibroids Clinical Trial
— PRIMROSE 1Official title:
A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Daily Oral Administration of OBE2109 Alone and in Combination With Add-back Therapy for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
Verified date | June 2021 |
Source | ObsEva SA |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objective of this study is to demonstrate the superior efficacy versus placebo of OBE2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Status | Completed |
Enrollment | 526 |
Est. completion date | April 12, 2021 |
Est. primary completion date | April 14, 2020 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Key Inclusion Criteria: - Premenopausal woman at screening. - Body Mass Index = 18 kg/m2. - Menstrual cycles = 21 days and = 40 days. - Presence of uterine fibroids. - Heavy menstrual blood loss for each of the 2 menstrual periods assessed at screening using the alkaline hematin method. Key Exclusion Criteria: - The subject is pregnant or breast-feeding or is planning a pregnancy within the duration of the treatment period of the study. - History of uterus surgery that would interfere with the study. - The subject's condition is so severe that she will require surgery within 6 months regardless of the treatment provided. - Undiagnosed abnormal uterine bleeding. - Significant risk of osteoporosis or history of, or known osteoporosis or other metabolic bone disease. |
Country | Name | City | State |
---|---|---|---|
United States | Site reference ID 211 | Arcadia | California |
United States | Site reference ID 155 | Austin | Texas |
United States | Site reference ID 238 | Austin | Texas |
United States | Site reference ID 100 | Bay City | Michigan |
United States | Site reference ID 201 | Beaumont | Texas |
United States | Site reference ID 237 | Bellevue | Washington |
United States | Site reference ID 192 | Birmingham | Alabama |
United States | Site reference ID 190 | Boca Raton | Florida |
United States | Site reference ID 231 | Boca Raton | Florida |
United States | Site reference ID 175 | Brooklyn | New York |
United States | Site reference ID 116 | Bryn Mawr | Pennsylvania |
United States | Site reference ID 184 | Cerritos | California |
United States | Site reference ID 174 | Champaign | Illinois |
United States | Site reference ID 159 | Chattanooga | Tennessee |
United States | Site reference ID 186 | Cincinnati | Ohio |
United States | Site reference ID 168 | Clearwater | Florida |
United States | Site reference ID 164 | Cleveland | Ohio |
United States | Site reference ID 163 | Columbus | Georgia |
United States | Site reference ID 247 | Corpus Christi | Texas |
United States | Site reference ID 183 | Dallas | Texas |
United States | Site reference ID 200 | Dallas | Texas |
United States | Site reference ID 216 | Dallas | Texas |
United States | Site reference ID 233 | DeLand | Florida |
United States | Site reference ID 144 | Denver | Colorado |
United States | Site reference ID 145 | Detroit | Michigan |
United States | Site reference ID 169 | Dothan | Alabama |
United States | Site reference ID 246 | Englewood | Colorado |
United States | Site reference ID 147 | Escondido | California |
United States | Site reference ID 230 | Fairfield | Ohio |
United States | Site reference ID 126 | Fall River | Massachusetts |
United States | Site reference ID 149 | Fall River | Massachusetts |
United States | Site reference ID 197 | Fort Lauderdale | Florida |
United States | Site reference ID 244 | Fort Worth | Texas |
United States | Site reference ID 250 | Fort Worth | Texas |
United States | Site reference ID 213 | Franklin | Ohio |
United States | Site reference ID 248 | Frederick | Maryland |
United States | Site reference ID 115 | Frisco | Texas |
United States | Site reference ID 104 | Greensboro | North Carolina |
United States | Site reference ID 195 | Hershey | Pennsylvania |
United States | Site reference ID 135 | Hialeah | Florida |
United States | Site reference ID 146 | Hialeah | Florida |
United States | Site reference ID 120 | Houston | Texas |
United States | Site reference ID 157 | Houston | Texas |
United States | Site reference ID 217 | Houston | Texas |
United States | Site reference ID 219 | Houston | Texas |
United States | Site reference ID 154 | Huntington Park | California |
United States | Site reference ID 359 | Idaho Falls | Idaho |
United States | Site reference ID 222 | Indiana | Pennsylvania |
United States | Site reference ID 191 | Jacksonville | Florida |
United States | Site reference ID 165 | Jenkintown | Pennsylvania |
United States | Site reference ID 235 | Knoxville | Tennessee |
United States | Site reference ID 176 | Lake Charles | Louisiana |
United States | Site reference ID 236 | Las Vegas | Nevada |
United States | Site reference ID 245 | Lawrenceville | New Jersey |
United States | Site reference ID 185 | Los Angeles | California |
United States | Site reference ID 204 | Loxahatchee Groves | Florida |
United States | Site reference ID 109 | Marrero | Louisiana |
United States | Site reference ID 180 | Memphis | Tennessee |
United States | Site reference ID 205 | Memphis | Tennessee |
United States | Site reference ID 352 | Meridian | Idaho |
United States | Site reference ID 106 | Miami | Florida |
United States | Site reference ID 110 | Miami | Florida |
United States | Site reference ID 127 | Miami | Florida |
United States | Site reference ID 137 | Miami | Florida |
United States | Site reference ID 142 | Miami | Florida |
United States | Site reference ID 117 | Miami Lakes | Florida |
United States | Site reference ID 134 | Miami Lakes | Florida |
United States | Site reference ID 129 | Miami Springs | Florida |
United States | Site reference ID 107 | Miramar | Florida |
United States | Site reference ID 138 | Missoula | Montana |
United States | Site reference ID 353 | Mobile | Alabama |
United States | Site reference ID 131 | Morehead City | North Carolina |
United States | Site reference ID 189 | New Haven | Connecticut |
United States | Site reference ID 124 | New Port Richey | Florida |
United States | Site reference ID 188 | New York | New York |
United States | Site reference ID 151 | Norcross | Georgia |
United States | Site reference ID 158 | Norcross | Georgia |
United States | Site reference ID 103 | Norfolk | Virginia |
United States | Site reference ID 171 | Norfolk | Virginia |
United States | Site reference ID 351 | North Charleston | South Carolina |
United States | Site reference ID 199 | Northridge | California |
United States | Site reference ID 182 | Oak Brook | Illinois |
United States | Site reference ID 140 | Orlando | Florida |
United States | Site reference ID 141 | Orlando | Florida |
United States | Site reference ID 111 | Panorama City | California |
United States | Site reference ID 218 | Pasadena | Texas |
United States | Site reference ID 242 | Phoenix | Arizona |
United States | Site reference ID 210 | Pittsburgh | Pennsylvania |
United States | Site reference ID 208 | Port Jefferson | New York |
United States | Site reference ID 102 | Raleigh | North Carolina |
United States | Site reference ID 123 | Richmond | Virginia |
United States | Site reference ID 166 | Sacramento | California |
United States | Site reference ID 170 | Saginaw | Michigan |
United States | Site reference ID 214 | Saginaw | Michigan |
United States | Site reference ID 207 | Saint Petersburg | Florida |
United States | Site reference ID 172 | San Antonio | Texas |
United States | Site reference ID 101 | San Diego | California |
United States | Site reference ID 150 | Sandy Springs | Georgia |
United States | Site reference ID 178 | Shawnee Mission | Kansas |
United States | Site reference ID 226 | Silver Spring | Maryland |
United States | Site reference ID 148 | Smithfield | Pennsylvania |
United States | Site reference ID 187 | Southern Pines | North Carolina |
United States | Site reference ID 358 | Spartanburg | South Carolina |
United States | Site reference ID 133 | Staten Island | New York |
United States | Site reference ID 113 | Tampa | Florida |
United States | Site reference ID 234 | Thornton | Colorado |
United States | Site reference ID 228 | Towson | Maryland |
United States | Site reference ID 355 | Tucson | Arizona |
United States | Site reference ID 239 | Upland | California |
United States | Site reference ID 232 | Vestavia Hills | Alabama |
United States | Site reference ID 105 | Washington | District of Columbia |
United States | Site reference ID 128 | Webster | Texas |
United States | Site reference ID 125 | West Jordan | Utah |
United States | Site reference ID 112 | Westminster | California |
United States | Site reference ID 354 | Wichita | Kansas |
United States | Site reference ID 119 | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
ObsEva SA |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Bone Mineral Density (BMD) | Assessed by dual-energy X-ray absorptiometry (DXA) scan | From baseline up to Week 76 | |
Other | Endometrial biopsy | Assessed by histology | From baseline up to Week 52 | |
Other | Adverse events | Frequency and severity of Treatment-Emergent Adverse Events | Up to Week 76 | |
Primary | Percentage of Responders based on menstrual blood loss (MBL) volume reduction at Week 24 | Assessed using the alkaline hematin method | From baseline to Week 24 | |
Secondary | Time to reduced menstrual blood loss | Assessed using the alkaline hematin method | Up to Week 52 | |
Secondary | Amenorrhea | Assessed using the alkaline hematin method | Up to Week 52 | |
Secondary | Time to amenorrhea | Up to Week 52 | ||
Secondary | Number of days of uterine bleeding for the last 28-day interval prior to Week 24 | Assessed using the alkaline hematin method | last 28-day interval prior to Week 24 | |
Secondary | Number of days of uterine bleeding for each 28-day interval | Assessed using the alkaline hematin method | Up to Week 52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01441635 -
Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids
|
Phase 2 | |
Completed |
NCT00958334 -
Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003
|
Phase 2 | |
Withdrawn |
NCT04567589 -
A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Healthcare Professionals in Canada
|
||
Recruiting |
NCT05078307 -
Evaluation of a Hysteroscopic Method With Vaporization in the Hysteroscopic Treatment of Submucosal Uterine Fibroids
|
N/A | |
Recruiting |
NCT02283502 -
Clinical Test of the MRgHIFU System on Uterine Fibroids
|
Phase 1 | |
Completed |
NCT01739621 -
Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200
|
Phase 2 | |
Completed |
NCT01631903 -
Extension of Study ZPV-200
|
Phase 2 | |
Withdrawn |
NCT00768742 -
Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study
|
N/A | |
Completed |
NCT00152256 -
A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids
|
Phase 3 | |
Not yet recruiting |
NCT03586947 -
Association Between Vitamin D and the Risk of Uterine Fibroids
|
N/A | |
Completed |
NCT02925494 -
An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
|
Phase 3 | |
Not yet recruiting |
NCT06055114 -
Study on Vaginal Microecology and Cervical Local Immune Function in Patients With Uterine Fibroids of Childbearing Age
|
||
Terminated |
NCT05026502 -
A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules
|
||
Withdrawn |
NCT04567095 -
A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Patients in Canada
|
||
Withdrawn |
NCT03699176 -
Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids
|
Phase 3 | |
Not yet recruiting |
NCT02884960 -
Safety and Efficacy of Embozene Microspheres for Uterine Fibroid Embolization
|
N/A | |
Completed |
NCT02472184 -
Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy
|
N/A | |
Terminated |
NCT01555073 -
Preemptive Analgesia Following Uterine Artery Embolization
|
Phase 4 | |
Completed |
NCT01452659 -
Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids
|
Phase 2 | |
Completed |
NCT01229826 -
Magnetic Resonance Elastography (MRE) of Uterine Fibroids
|
N/A |